Conor Killmurray | Authors

Patients with Cisplatin-ineligible mUC and High PD-L1 Expression Experience Clinical Benefit With Atezolizumab

February 12, 2021

Using the single-agent atezolizumab (Tecentriq) plus chemotherapy versus chemotherapy alone to treat patients in the front-line setting with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma (mUC) revealed additional clinical evidence.